Newsfeeds - Spark Newswire

1 minute read

Alimera Sciences Q3 EPS $(0.60) Misses $(0.52) Estimate, Sales $12.15M Miss $12.37M Estimate

Today, 11:18 PM

Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.52) by 15.38 percent. This is a 400 percent decrease over losses of $(0.12) per share from

ALIM

19 minute read

Earnings Scheduled For October 28, 2021

By Benzinga Insights

Today, 11:18 PM

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.

AAPL

4 minute read

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More

By Shanthi Rexaline

Today, 11:18 PM

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

ABBV

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 11:18 PM

ADVM

1 minute read

From BZ’s Small Cap Healthcare Conference: Alimera Sciences CEO Rick Eiswirth Begins Speaking

By Bill Haddad

Today, 11:18 PM

https://www.youtube.com/watch?v=XWCc7mhljCE

ALIM

1 minute read

Alimera Sciences Shares Spike To Session High Following Sam.gov $3.4M Contract Award Via Dept. Of Veterans Affairs

By Benzinga Newsdesk

Today, 11:18 PM

https://sam.gov/opp/afee7b92a92a40b5a35d984e0359693d/view

ALIM

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 11:18 PM

ALIM

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:18 PM

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.

ABSI

1 minute read

HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $12

By Benzinga Newsdesk

Today, 11:18 PM

HC Wainwright & Co. analyst Yi Chen maintains Alimera Sciences (NASDAQ:ALIM) with a Buy and lowers the price target from $16 to $12.

ALIM

1 minute read

Earnings

Recap: Alimera Sciences Q2 Earnings

By Benzinga Insights

Today, 11:18 PM

Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, which missed the estimate of $1.06.

ALIM